← Eichor
Study identifier: NCT06957093 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial

Condition: Diabetes Mellitus Type 2 (T2DM) · Artificial Intelligence (AI)  ·  Sponsor: The First Hospital of Jilin University

PhaseNA
Planned participants400
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Purpose: To evaluate the efficacy of artificial intelligence (AI)-based decision-making technology in managing glycated hemoglobin (HbA1c) and blood glucose levels compared to the control group. Methods: For the AI Intervention group, the patients will be trained to independently use the diabetes telemedicine platform application. Each patient will be equipped with a glucometer and exercise bracelet, and the data will be automatically transmitted to the medical server via Bluetooth. The healthcare platform will analyze the uploaded data and provide feedback suggestions on medication, diet, and exercise automatically. The platform will also monitor the medical and lifestyle data of the patients every two weeks, offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform. The platform is a digitally integrated healthcare platform that patients can use independently without the need for monitoring and assistance by healthcare professionals. The glucometer and pedometer bracelet will automatically connect to the platform through Bluetooth. The patient lab sheet identification and structured conversion system, AI for food picture identification and calorie calculation systems, and the AI decision-making system are on the cloud server. Patients upload image information, such as lab sheets and meal pictures, through the patient's diabetes mobile health system, and the cloud platform intelligently analyzes the patient'…

This description comes directly from the study's public registry record.

Talk to the study team

Chenglin Sun, Doctor  ·  +86 13944855718  ·  clsun213@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Hospital of Jilin UniversityChangchun, Jilin, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06957093